Comparison of Five Antihypertensive Monotherapies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional-Hygienic Therapy in the Treatment of Mild Hypertension Study (TOMHS)

Liebson, Philip R.; Grandits, Greg; Dianzumba, Sinda; Prineas, Ronald J.; Grimm, Richard H.; Neaton, James D.; Stamler, Jeremiah

doi:10.1161/01.cir.91.3.698

Cited by 286 publications

(145 citation statements)

References 47 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…10. After 12 months, in which all TOMHS participants received nutritional-hygienic treatment, there was no additional significant difference with regard to LV hypertrophy regression between the group that received low doses of active antihypertensive medications as opposed to placebo, with no significant interaction of treatment with sex.…”

Section: Female Sex and Clinical Variablesmentioning

confidence: 83%

“…After 12 months, in which all TOMHS participants received nutritional-hygienic treatment, there was no additional significant difference with regard to LV hypertrophy regression between the group that received low doses of active antihypertensive medications as opposed to placebo, with no significant interaction of treatment with sex. 10 Among LIFE patients, there was no systematic change in body weight in either sex between baseline and 12 months of follow-up. Similarly, Schmieder et al 29 showed in a meta-analysis of high-quality clinical trials that both systolic and diastolic blood pressure reductions were independent correlates of LV mass regression.…”

Section: Female Sex and Clinical Variablesmentioning

confidence: 87%

“…[7][8][9] Several studies have shown that most antihypertensive medications can regress LV hypertrophy, though perhaps with varying efficacy. [10][11][12] However, it remains unclear whether regression of LV hypertrophy differs between sexes. Thus, the present study was undertaken to determine whether sexrelated differences in LV mass regression exist in the participants of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study after 12 months of sustained antihypertensive treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study

et al. 2004

View full text Add to dashboard Cite

While left ventricular (LV) structure and function differ between hypertensive women and men, it remains unclear whether sex affects regression of LV hypertrophy with antihypertensive treatment. We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol. At enrolment, 177 women and 242 men were randomized to losartan-based treatment and 161 women and 247 men were randomized to atenolol-based treatment (sex difference ¼ NS). After 12 months of antihypertensive treatment, blood pressure was lowered similarly in women (152/83 from 174/97 mmHg) and men (149/85 from 173/99 mmHg; both Po0.001, sex difference ¼ NS), without significant change in body weight in either sex. Cardiac output and pulse pressure/stroke volume were equivalently reduced in both sexes (À0.2 vs À0.1 l/min and both -0.20 mmHg/ml/m 2 , respectively; both P ¼ NS). Absolute LV mass change after 12 months of antihypertensive treatment was greater in men than in women (À30 vs À24 g, P ¼ 0.01). However, after adjusting for baseline LV mass and randomized study treatment, LV mass reduction was greater in women than in men (À33 vs À23 g, P ¼ 0.001). LV mass regression was greater in women, by 8.072.8 g, after adjusting for baseline LV mass and randomized study treatment. After consideration of baseline LV mass and randomized study treatment, antihypertensive treatment regressed LV hypertrophy more in women. Further studies are needed to identify the mechanisms and prognostic implications of this sex-related difference.

show abstract

Section: Female Sex and Clinical Variablesmentioning

confidence: 83%

Section: Female Sex and Clinical Variablesmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Several studies have showed that cardiac hypertrophy is reversed disproportionately by various antihypertensive drugs [4].…”

Section: Nephropathy 4 Retinopathymentioning

confidence: 99%

Effect of Telmisartan on the Regression of the Left Ventricular Hypertrophy in the Patients of Essential Hypertension

Misra¹

2013

JCDR

View full text Add to dashboard Cite

Introduction: An increase in the Left Ventricular Mass as a result of muscle hypertrophy, has emerged as a powerful pressure independent risk factor for the cardiovascular mortality and morbidity. It is associated with a risk of death that is 3 times greater than the risk which is associated with hypertension alone. For the development of Left Ventricular Hypertrophy (LVH), in addition to a chronic increase in the pressure and/or volume overload, an elevation in the plasma ACE activity, plasma aldosterone levels, and the angiotensin-II concentrations play a major role .In this study, the effect of Telmisartan, a selective angiotension-II receptor blocker, was compared with that of Atenolol, a selective β 1 adrenergic receptor blocker, on the regression of LVH in the patients of essential hypertension. Material and Method:Essential hypertensive patients with LVH were selected for this study, as per the inclusion and exclusion criteria. This study was carried out on two groups of hypertensive patients with LVH: Group-1 : The patients who were taking telmisartan 80 mg OD. Group-2 :The patients who were taking atenolol 50 mg OD.The blood pressure was measured and echocardiography was done in both the groups, prior to the treatment and 6 months after the treatment in the

show abstract

“…In ALLHAT, the baseline rate of echocardiographic LVH were similar in all three treatment groups (B4.5%), but no follow-up echocardiographic data on LVM reported. In the Treatment of Mild Hypertension Study (TOMHS), 15 chlorthalidone led to a greater reduction in LVM than doxazosin, amlodipine, enalapril, and acebutolol in 844 stage 1 hypertensive participants (20% were black) at each follow-up visit for 4 years, despite equivalent BP reduction. Interestingly, in the participants with chlorthalidone added as a second agent, the demonstration of an additional decrease in LVM further suggests an independent effect of chlorthalidone on reduction of LVM.…”

mentioning

confidence: 99%

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?

2003

View full text Add to dashboard Cite

Comparison of Five Antihypertensive Monotherapies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional-Hygienic Therapy in the Treatment of Mild Hypertension Study (TOMHS)

Cited by 286 publications

References 47 publications

Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study

Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study

Effect of Telmisartan on the Regression of the Left Ventricular Hypertrophy in the Patients of Essential Hypertension

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?

Contact Info

Product

Resources

About